Published: 2019 April 09

Helicobacter Pylori Diagnostics Market Size, Competitive Landscape and Market Forecast - 2029

SKU : PH885
180 pages
Report Summary
Table of Contents
List of Tables & Figures

Helicobacter Pylori Diagnostics Market is segmented By Test Type (Invasive Tests (Histology, Rapid Urea Testing, Immunoassay), Non Invasive Tests (Stool Antigen Test, Serology Test, Urea Breath Test)), By End Users (Hospitals, Clinics, Diagnostic centers, Public health labs), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2022-2029


Helicobacter Pylori Diagnostics Market was valued at US$ 317.64 million in 2021 and is estimated to reach US$ 703.26 million by 2029, growing at a CAGR of 10.86% during the forecast period (2022-2029).      

Helicobacter Pylori Diagnostics Market



Market CAGR


Segments Covered

 By Testing Type, By Diagnostic Method, By End-User, and By Region

Report Insights Covered

Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights.

Fastest Growing Region

Asia Pacific

Largest Market Share 

North America

To Get a Free Sample Click here

Helicobacter pylori is a corkscrew-based bacteria identified in 1982 as a significant cause of chronic gastritis and stomach ulcers. These conditions are formerly believed to form by stress and poor diet. The symptoms of Helicobacter include stomach pain, bloating, tarry stools, and nausea. Blood, sweat, and breath are conventionally used to confirm the infection and followed by endoscopic examination for further insight into the disease.

It is also believed that Helicobacter pylori are present in the upper part of the gastrointestinal tract of around 50% of the world population. Point of Care is one of the most common tests to diagnose an infection.

Market Dynamics

There are various factors responsible for the growth of the market, such as an increase in the prevalence of helicobacter pylori infection across the globe and awareness among the population regarding the disease. An increase in the prevalence of the geriatric population as they are prone to frequent gastrointestinal infections is additionally contributing to the growth of the Helicobacter pylori diagnostics market.

The increasing number of novel product launches and the rising awareness will drive market growth.     

The global market for helicobacter pylori diagnostics is primarily driven by the surge in demand for these diagnostics; the rising number of novel product launches with non-invasive methods. An increase in helicobacter pylori cases is also aiding the market growth. Various latest diagnostics are being launched, contributing to the growth of the global helicobacter pylori diagnostics market. For instance, in Oct 2021, Meridian, a company providing diagnostic testing announced its launch of innovative Air Dryer qPCR mixes that detects RNA/DNA from urine samples.

Various funding, novel technological advancements, and the number of the latest, innovative product launches are increasing, leading to the high demand for helicobacter pylori diagnostics. For instance, in Jun 2022, Meridian Bioscience Inc., a diagnostic testing solutions provider announced two novel sample-specific master mixes, Lyo Ready Direct RNA/DNA qPCR stool mix and Lyo Ready Direct DNA qPCR stool mix that provides better DNA and RNA molecular detection from crude fecal specimens.

The high cost associated with diagnostic equipment will hamper the market’s growth.  

However, major factors hindering the global helicobacter pylori market during the forecast period are the high cost associated with the equipment and the presence of undiagnosed patients. The average cost of a real-time PCR machine costs around $15,000.

COVID-19 Impact Analysis

The pandemic has negatively impacted global financial expectations, operations and crisis response strategy. The COVID-19 outbreak has severely impacted the healthcare industry. The helicobacter pylori diagnostics market has experienced huge losses due to COVID, as all the research and clinical trials got affected due to the diversion of attention toward COVID. But now, the market participants are changing their long-term and short-term growth strategies by utilizing the research market and creating cutting-edge items to combat the pandemic. Various initiatives, collaborations and mergers are happening worldwide, boosting the market’s growth. For instance, in Apr 2020, Thermo Fisher created several PCR kits and tests for diagnostic and research to fight the COVID-19 outbreak. They released AcroMetrix Coronavirus 2019 (COVID-19) RNA Control after receiving the US FDA's emergency use authorization (EUA) for the SARS CoV 2 multiplex real-time PCR test.

Segment Analysis

The non-invasive devices segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)          

The non-invasive devices segment is the highest market holder in the global helicobacter pylori diagnostics market. Non-invasive methods growth is attributed to the increased adoption of the non-invasive type of diagnostic that includes the Urea breath test (UBT), Stool antigen test and Serology, primarily because it involves no pain and low cost. The growth trend will continue in the coming years, with new products being developed and introduced into the market. Companies are focusing on developing devices and solutions that are non-invasive or less invasive to achieve low recovery time, reduced soreness in the treated area, cheaper cost, a smaller or no incision during the procedure, and better efficacy.

The non-invasive device segment dominates the market due to the rising awareness of this disease. The growing number of regulatory approvals, technological advancements, product launches, and research studies drive the market’s growth. For instance, in Jul 2021, Meridian Biosciences Inc., diagnostic testing and life sciences raw material provider, announced its acquisition agreement for North American business BreathTek, a urea breath test for helicobacter pylori from Otsuka America Pharmaceutical Inc for around $20 million.

Geographical Analysis

North America holds the largest market share of the global helicobacter pylori diagnostics market.

North America dominates the global helicobacter pylori diagnostics market, primarily attributed to the increasing development in healthcare facilities and an increase in investment by government and non-government organizations for the development of new diagnostics devices. The increase in the adoption of helicobacter pylori eradication programs leading to demand diagnostic test products and the presence of key players in the region are contributing to the growth of the helicobacter pylori diagnostics market. According to the American Society of Plastic Surgeons report in 2020,

Moreover, the growing number of product launches is responsible for the market’s growth. Other factors, such as the high spending on these devices, stimulate the market’s growth. Many key developments, technological advancements, collaborations and agreements are taking place in this region. For instance, in Feb 2021, Quidel Corporation, a rapid diagnostic testing solution and molecular diagnostic system provider, announced its novel manufacturing facility in Carlsbad, CA, for producing the QuickVue products line.

Competitive Landscape

The helicobacter pylori diagnostics market is highly competitive with local and global companies’ presence. Thermo Fisher Scientific Inc., Bio-Rad Laboratories Inc., Quidel Corporation, Diasorin S.P.A, Meridian Bioscience, Inc, Abbott Laboratories, Owens & Minor Inc., Sekisui Diagnostics, Llc., Biomerieux, Quidel Corporation and more. The key players are adopting various growth strategies such as product launches, mergers & acquisitions, partnerships, and collaborations, contributing to the market’s growth. For instance, in Jul 2021, Ortho Clinical Diagnostics, an in-vitro diagnostics company, announced its agreement with Thermo Fisher Scientific for distribution by providing MAS Quality Controls and LabLink XL QA Software from VITROS QC solution of Ortho to its system customers.

Thermo Fisher Scientific Inc:


Thermo Fisher Scientific is a healthcare distributor company that serves science. They manufacture and market reagents, scientific instruments & equipment, consumables and software services. It was established in 1956 and is based in Waltham, Massachusetts, United States.

­Product Portfolio:

QuantStudio6 and 7 Pro Real-Time PCR Systems: These are PCR systems that are very flexible as they reinforce various kinds of applications and favorable conditions. The smartness of these systems is created to minimize contamination by making them run hands-free. Mobile phones can be used to schedule and even monitor the run. The QuantStudio 6 and 7 Pro systems contain 96-well blocks that comprise a technology known as VeriFlex that is used for specific temperature control.

Key Development: In Sep 2022, Thermo Fisher certified its Applied Biosystems QuantStudio 7 Pro Dx, a real-time PCR, as it fulfills all the requirements by novel in-vitro medical devices regulation. Now it includes the biosystem Diomni Software ecosystem to grant labs and developers tests to support flexible PCR testing.

The global helicobacter pylori diagnostics market report would provide access to approximately 40+ market data tables, 45+ figures, and 200 (approximate) pages.  

Trending Topics

Allergy Diagnostics Market

Tissue Diagnostics Market

Vehicle Diagnostics Market

Buy this report
Single User
Multiple User
Enterprise User
Proceed to Buy